Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.41 |
| ▸ | CHRNG | P07510 | 2/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27681431 | 0.98 | SLC6A4 (0.54) | SLC6A4SLC6A3SLC6A2OPRM1OPRD1 | |
| SCHEMBL28323043 | 0.94 | SLC6A3 (0.50) | SLC6A4SLC6A3SLC6A2OPRM1OPRD1 | |
| SCHEMBL1155345 | 0.90 | OPRM1 (0.50) | SLC6A4SLC6A3SLC6A2OPRM1OPRD1 | |
| SCHEMBL11362121 | 0.81 | OPRM1 (0.44) | SLC6A4SLC6A3SLC6A2OPRM1OPRD1 | |
| SCHEMBL652461 | 0.81 | DRD2 (0.62) | SLC6A4SLC6A3SLC6A2OPRM1OPRD1 | |
| SCHEMBL11796632 | 0.80 | KCNA3 (0.48) | SLC6A4SLC6A3SLC6A2OPRM1OPRD1 | |
| SCHEMBL8959998 | 0.80 | SLC6A3 (0.42) | SLC6A4SLC6A3SLC6A2OPRM1OPRD1 | |
| SCHEMBL11560742 | 0.79 | OPRD1 (0.52) | SLC6A4SLC6A3SLC6A2OPRM1OPRD1 | |
| SCHEMBL21078101 | 0.79 | OPRL1 (0.52) | SLC6A4SLC6A3OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL9311181 | 0.79 | SLC6A3 (0.41) | SLC6A4SLC6A3SLC6A2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121176-A1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Families of Spinal Muscular Atrophy (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-1765810-B1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2514748-B1 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-06-02 | — | — | US | disclosed |
| US-9067897-B2 | 2,4-Diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2514748-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | Families of Spinal Muscular Atrophy (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-05-12 | — | — | US | disclosed |
| US-7888366-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-02-15 | — | — | US | disclosed |
| EP-1765810-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | Decode Chemistry, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123724-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | SLC6A4 1887/4885SLC6A3 1143/4885SLC6A2 931/4885 |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | SLC6A4 1887/4885SLC6A3 1143/4885SLC6A2 931/4885 |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | SMN1; SMN2, MUSK, MYO3B | SLC6A4 1887/4885SLC6A3 1143/4885SLC6A2 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.